GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.

Automated summary

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease, affecting 70% of patients with diabetes. There are currently no specific drugs available for its treatment. GLP-1 receptor agonists (GLP-1 RAs) have shown significant impact on body weight and markers of fatty liver and fibrosis in NAFLD patients, in addition to their anti-hyperglycemic effect. This review aims to summarize the available evidence on the role of GLP-1 RAs in NAFLD treatment and propose potential future scenarios.